David Steinberg

General Partner

2019 - Current

Venture Partner

2018 - 2019

Chairman, Founding CEO

2021

Board Member, Founding CEO

2022

Board Member

2021

Chairman, Founding CEO

2020

Be Biopharma (www.be.bio) is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy

Board Member

2020

Founding CEO, former Chairman

2019 - 2021

Pyxis Oncology (NASDAQ:PYXS) is developing therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment. www.pyxisoncology.com

Co-Founder

2017 - 2020

Targeting the biology of aging to prevent or treat aging-related diseases

Founding CEO

2016 - 2018

Vor Biopharma (NASDAQ:VOR) is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.

Founding CEO

2011 - 2018

Rationally designing medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.